Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients
Open Access
- 1 April 2005
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (4), 398-404
- https://doi.org/10.1111/j.1365-2125.2005.02337.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical TrialThe Journal of Infectious Diseases, 2004
- Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2003
- Diurnal variation of plasma protease inhibitor concentrationsAIDS, 2002
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionThe New England Journal of Medicine, 2002
- Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced PatientsThe Journal of Infectious Diseases, 2002
- RitonavirClinical Pharmacokinetics, 1998
- ChronopharmacokineticsClinical Pharmacokinetics, 1998
- Circadian changes in estimated hepatic blood flow in healthy subjects.British Journal of Clinical Pharmacology, 1991
- Chronopharmacokinetics and Cardiovascular Effects of NifedipineChronobiology International, 1991